CSIMarket
 
Atai Life Sciences N v   (ATAI)
Other Ticker:  
 
 
Price: $1.6600 $0.05 3.106%
Day's High: $1.69 Week Perf: -1.19 %
Day's Low: $ 1.62 30 Day Perf: -13.99 %
Volume (M): 692 52 Wk High: $ 2.85
Volume (M$): $ 1,149 52 Wk Avg: $1.67
Open: $1.68 52 Wk Low: $1.03



 Market Capitalization (Millions $) 295
 Shares Outstanding (Millions) 178
 Employees -
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -71
 Cash Flow (TTM) (Millions $) -66
 Capital Exp. (TTM) (Millions $) 1

Atai Life Sciences N V
Atai Life Sciences N.V. is a global biotech company that specializes in developing transformative therapies for mental health disorders. The company focuses on discovering and developing innovative treatments for conditions such as depression, anxiety, addiction, and other related disorders. They strive to address the unmet needs in mental health by utilizing cutting-edge research, technology, and strategic partnerships. Atai Life Sciences aims to improve the way mental health disorders are diagnosed, treated, and understood to ultimately enhance the quality of life for individuals suffering from these conditions.


   Company Address: ATAI Life Sciences N.V. Berlin 0
   Company Phone Number: 2153 9035   Stock Exchange / Ticker: NASDAQ ATAI
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Groundbreaking Study Commences: atai Life Sciences Initiates Dosing of BPL-003 in Phase 2a Trial for Treatment-Resistant Depression

Published Wed, Apr 24 2024 11:01 AM UTC

atai Life Sciences, a renowned clinical-stage biopharmaceutical company focused on revolutionizing the treatment of mental health disorders, has successfully administered the first dose of BPL-003 (intranasal 5-MeO-DMT) to a patient in the second phase of Beckley Psytech's Phase 2a clinical trial. This groundbreaking study aims to explore the potential benefits of BPL-003 as...

Clinical Study

BPL-003: A Promising Breakthrough for Mental Health Treatment Revealed in Phase 1 Study

Published Wed, Apr 17 2024 11:00 AM UTC

Phase 1 Study of BPL-003 Shows Promise in Treating Mental Health Disorders is pleased to present the findings of the Phase 1 study of BPL-003, a novel synthetic intranasal benzoate salt formulation of 5-MeO-DMT, conducted by Beckley Psytech, a subsidiary of atai Life Sciences. This study aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BP...

Clinical Study

Intranasal Psychedelic Drug Showcases Promising Results for Treatment Resistant Depression: A Fresh Chapter in Mental Health Resurgence

Published Wed, Mar 27 2024 11:01 AM UTC

In a recent ground-breaking development for the treatment of treatment-resistant depression (TRD), atai Life Sciences, a major player in psychedelic therapeutics sector, announced preliminary results from a phase 2a open-label study of BPL-003, conducted in collaboration with Beckley Psytech. BPL-003 is an intranasal formulation of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT...

Partnership

atai Life Sciences Partners with Beckley Psytech to Revolutionize Mental Health Treatment through Short-Duration Psychedelics

Published Thu, Jan 4 2024 12:00 PM UTC

The collaboration between atai Life Sciences and Beckley Psytech is aimed at accelerating the clinical development of short-duration psychedelics. These substances have shown promise in rapidly alleviating symptoms of various mental health disorders, including depression, anxiety, PTSD, and addiction.By investing in Beckley Psytech, atai Life Sciences is positioning itself a...

Clinical Study

Positive Results from EMP-01 Phase 1 Study: A Promising Breakthrough in Mental Health Treatment

Published Tue, Jan 2 2024 1:01 PM UTC

atai Life Sciences, a renowned clinical-stage biopharmaceutical company dedicated to revolutionizing mental health disorder treatments, has recently disclosed encouraging findings from their Phase 1 study involving EMP-01 (R-MDMA). This orally administered drug, derived from the well-known MDMA (3,4-methylenedioxy-methamphetamine), has demonstrated significant potential in a...






 

Atai Life Sciences N V's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com